February 1, 2019 Today, Lupus Therapeutics, an affiliate of Lupus Research Alliance, is launching our Patient Advocates for Lupus Studies (PALS) program with a pilot study to determine its effectiveness in increasing awareness of and participation in lupus clinical trials, particularly among diverse populations. The program will pair people with lupus interested in learning about […] READ MORE
January 24, 2019 A recent review article in Lupus Science & Medicine provides a valuable overview of the “10 most important contemporary challenges in the management of SLE” according to a multidisciplinary team of clinicians, pharmacists and researchers from several clinics and patient organizations in France. Their top 10 challenges include several critical factors that the […] READ MORE
February 1, 2019 The Lupus Research Alliance announced that its affiliate Lupus Therapeutics is working with the pharmaceutical company, Janssen, to help conduct a Phase 3 trial to evaluate whether their drug ustekinumab (Stelara®) may offer benefit to people with lupus. Called LOTUS, the international study is being conducted in over 200 sites, 20 of […] READ MORE
January 21, 2019 A study just published in Annals of Internal Medicine showed that kidney transplantation reduced deaths due to lupus nephritis — kidney inflammation caused by lupus. Up to 60 percent of people with SLE are diagnosed with lupus nephritis, which can lead to significant illness and even death. According to the National Institute of Diabetes […] READ MORE
January 18, 2019 An observational study published in Lupus of people with lupus found that of six factors, stress, depression and pain contributed most to fatigue, one of the most debilitating symptoms of the disease. The study involved 116 ethnically diverse, primarily female participants (91%) diagnosed with lupus receiving care at university medical centers. Each […] READ MORE
January 14, 2019 A small randomized Phase 1 study published in Arthritis & Rheumatology found that the existing asthma treatment omalizumab (Xolair) may improve lupus activity by reducing production of type 1 interferons. The study involved 15 patients with lupus who had elevated amounts of an antibody immunoglobulin E and a minimum level of disease […] READ MORE
January 8, 2019 Source: Idorsia LTD Press Release Idorsia Ltd (SIX: IDIA) announced that the first patient has been enrolled into a multiple-dose study to evaluate the efficacy and safety of cenerimod, a selective S1P1 receptor modulator for the treatment of adults with systemic lupus erythematosus (SLE). Idorsia is investigating cenerimod, an oral once-daily tablet in […] READ MORE
NEW YORK, NY – January 10. Can “borrowed” drugs for treating other diseases protect the skin in patients with lupus? Can researchers coax the body to weed out harmful immune cells that drive tissue destruction in lupus? Those are just two of the innovative approaches for lupus therapies recognized by the Lupus Research Alliance with […] READ MORE
January 7, 2019 The 2018 Forum for Discovery opened with a series of lectures on new research on the role of our innate immune system in lupus and how discoveries may lead to new therapies. Roles of the cGAS Pathway in Lupus Zhijian (James) Chen, PhD, Professor of Molecular Biology at the University of Texas Southwestern […] READ MORE
One session at our recent scientific conference Forum for Discovery was devoted to meeting the need for new approaches to lupus and the challenges faced in “translating” what is learned by researchers into therapies that will help patients with lupus. Gerald Nepom, MD, PhD, Co-Chair of LRFs Scientific Advisory Board and Director of the Benaroya Research […] READ MORE
Researchers have long known that lupus and other autoimmune disorders tend to run in families. However, the inheritance pattern is in most cases unknown. And not everyone who inherits a gene variation that increases the chance of developing lupus, will develop lupus. That is why genetics of lupus is a key area of research. Over […] READ MORE
January 4, 2019 A study just published in Clinical and Experimental Rheumatology found that exposure to periodontal bacteria on the gums around the teeth can increase lupus disease activity. The team of researchers at Oklahoma Medical Research Foundation examined blood samples from lupus patients to measure the amount of antibodies formed against specific bacteria. They […] READ MORE
